Alkyl-substituted pyrazolopyrimidines
11 claims: 11 independent, 0 dependent
- 1Composés de formule dans laquelle R1 est un reste alkyle en C1 à C6, trifluorométhyle, hydroxy, alkoxy en C1 à C6, -C(=O)OR5 ou -C(=O)NR6R7, le reste alkyle en C1 à C6 étant éventuellement substitué avec un à trois restes choisis, indépendamment les uns des autres, dans le groupe des restes hydroxy, alkoxy en C1 à C6, halogéno, trifluorométhyle, trifluorométhoxy, -C(=O)OR5 ou -C(=O)NR6R7, et R5 est un reste alkyle en C1 à C6,R6 et R7 représentent, indépendamment l'un de l'autre, l'hydrogène, un reste aryle en C6 à C10, alkyle en C1 à C6, ou bien ils forment conjointement avec l'atome d'azote auxquels ils sont liés un groupe hétérocyclyle tétragonal à décagonal,R2 représente l'hydrogène, un reste alkyle en C1 à C6, trifluorométhyle, alkoxy en C1 à C6, ou bien R1 et R2 forment, conjointement avec l'atome de carbone auquel ils sont liés, un reste cycloalkyle en C3 à C8, cycloalcényle en C3 à C8 ou hétérocyclyle tétragonal à décagonal, qui portent éventuellement jusqu'à deux substituants choisis dans le groupe des substituants alkyle en C1 à C6, alkoxy en C1 à C6, hydroxy, oxo, -C(=O)OR8, et R8 est un reste alkyle en C1 à C6 ou benzyle,R3 représente l'hydrogène ou un reste alkyle en C1 à C6,R4 est un reste pentane-3-yle, cycloalkyle en C3 à C6,X représente l'oxygène ou le soufre, ainsi que leurs sels, leurs produits de solvatation et/ou les produits de solvatation de leurs sels. Compounds of the formula in which R1 is C1-C6-alkyl, trifluoromethyl, hydroxy, C1-C6-alkoxy, -C(=O)OR5 or -C(=O)NR6R7, where C1-C6-alkyl is optionally substituted by 1 to 3 radicals independently of one another selected from the group of hydroxy, C1-C6-alkoxy, halogen, trifluoromethyl, trifluoromethoxy, -C(=O)OR5 or -C(=O)NR6R7, and R5 is C1-C6-alkyl,R6 and R7 are independently of one another hydrogen, C6-C10-aryl, C1-C6-alkyl, or together with the nitrogen atom to which they are bonded form a 4- to 10-membered heterocyclyl,R2 is hydrogen, C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, orR1 and R2 together with the carbon atom to which they are bonded form C3-C8-cycloalkyl, C3-C8-cycloalkenyl or 4- to 10-membered heterocyclyl, which are optionally substituted by up to 2 substituents from the group of C1-C6-alkyl, C1-C6-alkoxy, hydroxy, oxo, -C(=O)OR8, and R8 is C1-C6-alkyl or benzyl,R3 is hydrogen or C1-C6-alkyl,R4 is pentan-3-yl, C3-C6-cycloalkyl,X is oxygen or sulphur, and the salts, solvates and/or solvates of the salts thereof. Verbindungen der Formel in welcher R1 C1-C6-Alkyl, Trifluormethyl, Hydroxy, C1-C6-Alkoxy, -C(=O)OR5 oder -C(=O)NR6R7, wobei C1-C6-Alkyl gegebenenfalls mit 1 bis 3 Resten unabhängig voneinander ausgewählt aus der Gruppe Hydroxy, C1-C6-Alkoxy, Halogen, Trifluormethyl, Trifluormethoxy, -C(=O)OR5 oder -C(=O)NR6R7 substituiert ist, und R5 für C1-C6-Alkyl,R6 und R7 unabhängig voneinander für Wasserstoff, C6-C10-Aryl, C1-C6-Alkyl stehen, oder zusammen mit dem Stickstoffatom, an das sie gebunden sind, ein 4- bis 10-gliedriges Heterocyclyl bilden,R2 Wasserstoff, C1-C6-Alkyl, Trifluormethyl, C1-C6-Alkoxy, oder R1 und R2 zusammen mit dem Kohlenstoffatom, an das sie gebunden sind, C3-C8-Cycloalkyl, C3-C8-Cycloalkenyl oder 4- bis 10-gliedriges Heterocyclyl bilden, die gegebenenfalls mit bis zu 2 Substituenten aus der Gruppe C1-C6-Alkyl, C1-C6-Alkoxy, Hydroxy, Oxo, -C(=O)OR8 substituiert sind, und R8 für C1-C6-Alkyl oder Benzyl steht,R3 Wasserstoff oder C1-C6-Alkyl,R4 Pentan-3-yl, C3-C6-Cycloalkyl,X Sauerstoff oder Schwefel, bedeuten, sowie deren Salze, Solvate und/oder Solvate der Salze.
- 2Composés suivant la revendication 1, dans lesquels R1 est un reste alkyle en C1 à C6, hydroxy, alkoxy en C1 à C6, -C(=O)OR5 ou -C(=O)NR6R7, le reste alkyle en C1 à C6 portant éventuellement un substituant hydroxy, alkoxy en C1 à C6, -C(=O)OR5 ou -C(=O)NR6R7, et R5 est un reste alkyle en C1 à C6,R6 et R7 représentent, indépendamment l'un de l'autre, l'hydrogène, un reste aryle en C6 à C10 ou alkyle en C1 à C6, ou forment conjointement avec l'atome d'azote auxquels ils sont liés un reste hétérocyclyle tétragonal à décagonal,R2 représente l'hydrogène, un reste alkyle en C1 à C6, alkoxy en C1 à C6, ou bien R1 et R2 forment, conjointement avec l'atome de carbone auquel ils sont liés, un reste cycloalkyle en C3 à C8, cycloalcényle en C3 à C8 ou hétérocyclyle tétragonal à décagonal, qui portent éventuellement jusqu'à deux substituants du groupe des substituants alkyle en C1 à C6, alkoxy en C1 à C6, hydroxy, oxo, -C(=O)OR8, et R8 est un reste alkyle en C1 à C6 ou benzyle,R3 représente l'hydrogène ou un reste alkyle en C1 à C6,R4 est un reste pentane-3-yle, cycloalkyle en C4 à C6,X représente l'oxygène ou le soufre, ainsi que leurs sels, leurs produits de solvatation et/ou les produits de solvatation de leurs sels. Compounds according to Claim 1, wherein R1 is C1-C6-alkyl, hydroxy, C1-C6-alkoxy, -C(=O)OR5 or -C(=O)NR6R7, where C1-C6-alkyl is optionally substituted by hydroxy, C1-C6-alkoxy, -C(=O)OR5 or -C(=O)NR6R7, and R5 is C1-C6-alkyl,R6 and R7 are independently of one another hydrogen, C6-C10-aryl, C1-C6-alkyl, or together with the nitrogen atom to which they are bonded form a 4- to 10-membered heterocyclyl,R2 is hydrogen, C1-C6-alkyl, C1-C6-alkoxy, orR1 and R2 together with the carbon atom to which they are bonded form C3-C8-cycloalkyl, C3-C8-cycloalkenyl or 4- to 10-membered heterocyclyl, which are optionally substituted by up to 2 substituents from the group of C1-C6-alkyl, C1-C6-alkoxy, hydroxy, oxo, -C(=O)OR8, and R8 is C1-C6-alkyl or benzyl,R3 is hydrogen or C1-C6-alkyl,R4 is pentan-3-yl, C4-C6-cycloalkyl,X is oxygen or sulphur, and the salts, solvates and/or solvates of the salts thereof. Verbindungen nach Anspruch 1, wobei R1 C1-C6-Alkyl, Hydroxy, C1-C6-Alkoxy, -C(=O)OR5 oder -C(=O)NR6R7, wobei C1-C6-Alkyl gegebenenfalls mit Hydroxy, C1-C6-Alkoxy, -C(=O)OR5 oder -C(=O)NR6R7 substituiert ist, und R5 für C1-C6-Alkyl,R6 und R7 unabhängig voneinander für Wasserstoff, C6-C10-Aryl, C1-C6-Alkyl stehen, oder zusammen mit dem Stickstoffatom, an das sie gebunden sind, ein 4- bis 10-gliedriges Heterocyclyl bilden,R2 Wasserstoff, C1-C6-Alkyl, C1-C6-Alkoxy, oder R1 und R2 zusammen mit dem Kohlenstoffatom, an das sie gebunden sind, C3-C8-Cycloalkyl, C3-C8-Cycloalkenyl oder 4- bis 10-gliedriges Heterocyclyl bilden, die gegebenenfalls mit bis zu 2 Substituenten aus der Gruppe C1-C6-Alkyl, C1-C6-Alkoxy, Hydroxy, Oxo, -C(=O)OR8 substituiert sind, und R8 für C1-C6-Alkyl oder Benzyl steht,R3 Wasserstoff oder C1-C6-Alkyl,R4 Pentan-3-yl, C4-C6-Cycloalkyl,X Sauerstoff oder Schwefel, bedeuten, sowie deren Salze, Solvate und/oder Solvate der Salze.
- 3Composés suivant les revendications 1 et 2, dans lesquels R1 est un reste alkyle en C1 à C4, hydroxy, alkoxy en C1 à C4, -C(=O)OR5 ou -C(=O)NR6R7, le reste alkyle en C1 à C4 portant éventuellement un substituant hydroxy, trifluorométhyle, alkoxy en C1 à C4, -C(=O)OR5 ou -C(=O)NR6R7, et R5 est un reste alkyle en C1 à C4,R6 et R7 représentent, indépendamment l'un de l'autre, l'hydrogène, un reste phényle, alkyle en C1 à C6, ou forment conjointement avec l'atome d'azote auxquels ils sont liés un groupe hétérocyclyle pentagonal ou hexagonal,R2 représente l'hydrogène, un reste alkyle en C1 à C4, trifluorométhyle, alkoxy en C1 à C4, ou bien R1 et R2 forment, conjointement avec l'atome de carbone auquel ils sont liés, un reste cycloalkyle en C5 ou C6, cycloalcényle en C5 ou C6 ou hétérocyclyle pentagonal ou hexagonal, qui portent éventuellement jusqu'à deux substituants du groupe des substituants alkyle en C1 à C4, alkoxy en C1 à C4, hydroxy, oxo, -C(=O)OR8, et R8 est un reste alkyle en C1 à C4 ou benzyle,R3 représente l'hydrogène,R4 est un reste pentane-3-yle, cycloalkyle en C5 ou C6,X représente l'oxygène ou le soufre, ainsi que leurs sels, leurs produits de solvatation et/ou les produits de solvatation de leurs sels. Compounds according to Claims 1 and 2, wherein R1 is C1-C4-alkyl, hydroxy, C1-C4-alkoxy, -C(=O)OR5 or -C(=O)NR6R7, where C1-C4-alkyl is optionally substituted by hydroxy, trifluoromethyl, C1-C4-alkoxy, -C(=O)OR5 or -C(=O)NR6R7, and R5 is C1-C4-alkyl,R6 and R7 are independently of one another hydrogen, phenyl, C1-C4-alkyl, or together with the nitrogen atom to which they are bonded form a 5- to 6-membered heterocyclyl,R2 is hydrogen, C1-C4-alkyl, trifluoromethyl, C1-C4-alkoxy, orR1 and R2 together with the carbon atom to which they are bonded form C5-C6-cycloalkyl, C5-C6-cycloalkenyl or 5- to 6-membered heterocyclyl, which are optionally substituted by up to 2 substituents from the group of C1-C4-alkyl, C1-C4-alkoxy, hydroxy, oxo, -C(=O)OR8, and R8 is C1-C4-alkyl or benzyl,R3 is hydrogen,R4 is pentan-3-yl, C5-C6-cycloalkyl,X is oxygen or sulphur, and the salts, solvates and/or solvates of the salts thereof. Verbindungen nach Ansprüchen 1 und 2, wobei R1 C1-C4-Alkyl, Hydroxy, C1-C4-Alkoxy, -C(=O)OR5 oder -C(=O)NR6R7, wobei C1-C4-Alkyl gegebenenfalls mit Hydroxy, Trifluormethyl, C1-C4-Alkoxy, -C(=O)OR5 oder -C(=O)NR6R7 substituiert ist, und R5 für C1-C4-Alkyl,R6 und R7 unabhängig voneinander für Wasserstoff, Phenyl, C1-C4-Alkyl stehen, oder zusammen mit dem Stickstoffatom, an das sie gebunden sind, ein 5- bis 6-gliedriges Heterocyclyl bilden,R2 Wasserstoff, C1-C4-Alkyl, Trifluormethyl, C1-C4-Alkoxy, oder R1 und R2 zusammen mit dem Kohlenstoffatom, an das sie gebunden sind, C5-C6-Cycloalkyl, C5-C6-Cycloalkenyl oder 5- bis 6-gliedriges Heterocyclyl bilden, die gegebenenfalls mit bis zu 2 Substituenten aus der Gruppe C1-C4-Alkyl, C1-C4-Alkoxy, Hydroxy, Oxo, -C(=O)OR8 substituiert sind, und R8 für C1-C4-Alkyl oder Benzyl steht,R3 Wasserstoff,R4 Pentan-3-yl, C5-C6-Cycloalkyl,X Sauerstoff oder Schwefel, bedeuten, sowie deren Salze, Solvate und/oder Solvate der Salze.
- 4Composés suivant les revendications 1 à 3, dans lesquels R1 est un reste méthyle, éthyle, isopropyle, trifluorométhyle, méthoxycarbonyle, éthoxycarbonyle ou -C(=O)NR6R7, le reste méthyle portant éventuellement un substituant méthoxycarbonyle ou éthoxycarbonyle, et R6 est un reste phényle, etR7 représente l'hydrogène,R2 représente l'hydrogène, un reste méthyle, trifluorométhyle, ou bien R1 et R2 forment, conjointement avec l'atome de carbone auquel ils sont liés, un reste cyclopentyle, cyclohexyle, cyclopentényle ou tétrahydrofuryle, le reste cyclohexyle portant éventuellement un substituant méthyle, etR3 représente l'hydrogène,R4 est un reste pentane-3-yle, cycloalkyle en C5 ou C6,X représente l'oxygène ou le soufre, ainsi que leurs sels, leurs produits de solvatation et/ou les produits de solvatation de leurs sels. Compounds according to Claims 1 to 3, wherein R1 is methyl, ethyl, isopropyl, trifluoromethyl, methoxycarbonyl, ethoxycarbonyl or -C(=O)NR6R7, where methyl is optionally substituted by methoxycarbonyl or ethoxycarbonyl, and R6 is phenyl andR7 is hydrogen,R2 is hydrogen, methyl, trifluoromethyl, orR1 and R2 together with the carbon atom to which they are bonded form cyclopentyl, cyclohexyl, cyclopentenyl or tetrahydrofuryl, where cyclohexyl is optionally substituted by methyl, andR3 is hydrogen,R4 is pentan-3-yl, C5-C6-cycloalkyl,X is oxygen or sulphur, and the salts, solvates and/or solvates of the salts thereof. Verbindungen nach Ansprüchen 1 bis 3, wobei R1 Methyl, Ethyl, Isopropyl, Trifluormethyl, Methoxycarbonyl, Ethoxycarbonyl oder -C(=O)NR6R7, wobei Methyl gegebenenfalls mit Methoxycarbonyl oder Ethoxycarbonyl substituiert ist, und R6 für Phenyl steht undR7 für Wasserstoff steht,R2 Wasserstoff, Methyl, Trifluormethyl, oderR1 und R2 zusammen mit dem Kohlenstoffatom, an das sie gebunden sind, Cyclopentyl, Cyclohexyl, Cyclopentenyl oder Tetrahydrofuryl bilden, wobei Cyclohexyl gegebenenfalls mit Methyl substituiert ist, undR3 Wasserstoff,R4 Pentan-3-yl, C5-C6-Cycloalkyl,X Sauerstoff oder Schwefel, bedeuten, sowie deren Salze, Solvate und/oder Solvate der Salze.
- 5Composés suivant les revendications 1 à 4, dans lesquels R1 est un reste méthyle, éthyle, isopropyle, méthoxycarbonyle, éthoxycarbonyle ou -C(=O)NR6R7, le reste méthyle portant éventuellement un substituant méthoxycarbonyle ou éthoxycarbonyle, et R6 est un reste phényle, etR7 représente l'hydrogène,R2 représente l'hydrogène, un reste méthyle, ou bien R1 et R2 forment, conjointement avec l'atome de carbone auquel ils sont liés, un reste cyclopentyle, cyclohexyle, cyclopentényle ou tétrahydrofuryle, le reste cyclohexyle portant éventuellement un substituant méthyle, etR3 représente l'hydrogène,R4 est un reste pentane-3-yle, cycloalkyle en C5 ou C6,X représente l'oxygène, ainsi que leurs sels, leurs produits de solvatation et/ou les produits de solvatation de leurs sels. Compounds according to Claims 1 to 4, wherein R1 is methyl, ethyl, isopropyl, methoxycarbonyl, ethoxycarbonyl or C(=O)NR6R7, where methyl is optionally substituted by methoxycarbonyl or ethoxycarbonyl, and R6 is phenyl andR7 is hydrogen,R2 is hydrogen, methyl, orR1 and R2 together with the carbon atom to which they are bonded form cyclopentyl, cyclohexyl, cyclopentenyl or tetrahydrofuryl, where cyclohexyl is optionally substituted by methyl, andR3 is hydrogen,R4 is pentan-3-yl, C5-C6-cycloalkyl,X is oxygen, and the salts, solvates and/or solvates of the salts thereof. Verbindungen nach Ansprüchen 1 bis 4, wobei R1 Methyl, Ethyl, Isopropyl, Methoxycarbonyl, Ethoxycarbonyl oder -C(=O)NR6R7, wobei Methyl gegebenenfalls mit Methoxycarbonyl oder Ethoxycarbonyl substituiert ist, und R6 für Phenyl undR7 für Wasserstoff stehen,R2 Wasserstoff, Methyl, oderR1 und R2 zusammen mit dem Kohlenstoffatom, an das sie gebunden sind, Cyclopentyl, Cyclohexyl, Cyclopentenyl oder Tetrahydrofuryl bilden, wobei Cyclohexyl gegebenenfalls mit Methyl substituiert ist, undR3 Wasserstoff,R4 Pentan-3-yl, C5-C6-Cycloalkyl,X Sauerstoff, bedeuten, sowie deren Salze, Solvate und/oder Solvate der Salze.
- 6Process for preparing compounds according to Claims 1 to 5, characterized in that[A] compounds of the formula in which R4 has the meanings indicated above, are converted by reaction with a compound of the formula in which R1, R2 and R3 have the meanings indicated above, and Z is chlorine or bromine, in an inert solvent and in the presence of a base initially into compounds of the formula in which R1, R2, R3 and R4 have the meanings indicated above, then cyclized in an inert solvent and in the presence of a base to compounds of the formula in which R1, R2, R3 and R4 have the meanings indicated above, or[B] compounds of the formula (II) are reacted, with direct cyclization to (IA), with a compound of the formula in which R1, R2 and R3 have the meanings indicated above and R9 is methyl or ethyl, in an inert solvent and in the presence of a base, or[C] compounds of the formula in which R4 has the meanings indicated above, are initially converted by reaction with a compound of the formula (IIIa) in an inert solvent and in the presence of a base into compounds of the formula in which R1, R2, R3 and R4 have the meanings indicated above, and the latter are cyclized in a second step in an inert solvent and in the presence of a base and of an oxidizing agent to (IA), and the compounds of the formula (IA) are where appropriate then converted by reaction with a sulphurizing agent such as, for example, diphosphorus pentasulphide into the thiono derivatives of the formula in which R1, R2, R3 and R4 have the meanings indicated above, and the resulting compounds of the formula (I) are reacted where appropriate with the appropriate (i) solvents and/or (ii) bases or acids to give the solvates, salts and/or solvates of the salts thereof. Procédé de production de composés suivant les revendications 1 à 5, caractérisé en ce que :[A] on transforme tout d'abord des composés de formule dans laquelle R4 a les définitions indiquées ci-dessus, par réaction avec un composé de formule dans laquelle R1, R2 et R3 ont les définitions indiquées ci-dessus, et Z représente le chlore ou le brome, dans un solvant inerte et en présence d'une base, en composés de formule dans laquelle R1, R2, R3 et R4 ont les définitions indiquées ci-dessus, qu'on cyclise ensuite dans un solvant inerte, en présence d'une base, en composés de formule dans laquelle R1, R2, R3 et R4 ont les définitions indiquées ci-dessus, ou bien[B] on fait réagir des composés de formule (II), avec cyclisation directe en (IA) avec un composé de formule dans laquelle R1, R2 et R3 ont les définitions indiquées ci-dessus, et R9 est un reste méthyle ou éthyle, dans un solvant inerte et en présence d'une base, ou bien[C] on transforme tout d'abord des composés de formule dans laquelle R4 a les définitions indiquées ci-dessus, par réaction avec un composé de formule (IIIa) dans un solvant inerte et en présence d'une base, en composés de formule dans laquelle R1, R2, R3 et R4 ont les définitions indiquées ci-dessus, qu'on cyclise dans une seconde étape en (IA) dans un solvant inerte et en présence d'une base et d'un agent oxydant, puis on transforme éventuellement les composés de formule (IA), par réaction avec un agent de sulfuration tel que, par exemple, le pentasulfure de diphosphore, en les dérivés thiono de formule dans laquelle R1, R2, R3 et R4 ont les définitions indiquées ci-dessus, et on fait réagir éventuellement les composés résultants de formule (I) avec (i) des solvants convenables et/ou (ii) des bases ou acides convenables pour former leurs produits de solvatation, leurs sels et/ou des produits de solvatation de leurs sels. Verfahren zur Herstellung von Verbindungen nach Ansprüchen 1 bis 5, dadurch gekennzeichnet, dass man [A] Verbindungen der Formel in welcher R4 die oben angegebenen Bedeutungen hat, durch Umsetzung mit einer Verbindung der Formel in welcher R1, R2 und R3 die oben angegebenen Bedeutungen haben, und Z für Chlor oder Brom steht, in einem inerten Lösemittel und in Anwesenheit einer Base zunächst in Verbindungen der Formel in welcher R1, R2, R3 und R4 die oben angegebenen Bedeutungen haben, überführt, dann in einem inerten Lösemittel in Gegenwart einer Base zu Verbindungen der Formel in welcher R1, R2, R3 und R4 die oben angegebenen Bedeutungen haben, cyclisiert, oder[B] Verbindungen der Formel (II) unter direkter Cyclisierung zu (IA) mit einer Verbindung der Formel in welcher R1, R2 und R3 die oben angegebenen Bedeutungen haben und R9 für Methyl oder Ethyl steht, in einem inerten Lösemittel und in Anwesenheit einer Base umsetzt, oder[C] Verbindungen der Formel in welcher R4 die oben angegebenen Bedeutungen hat, zunächst durch Umsetzung mit einer Verbindung der Formel (IIIa) in einem inerten Lösemittel und in Anwesenheit einer Base in Verbindungen der Formel in welcher R1, R2, R3 und R4 die oben angegebenen Bedeutungen haben, überführt, und diese in einem zweiten Schritt in einem inerten Lösemittel und in Anwesenheit einer Base und eines Oxidationsmittels zu (IA) cyclisiert, und die Verbindungen der Formel (IA) gegebenenfalls dann durch Umsetzung mit einem Schwefelungsmittel wie beispielsweise Diphosphorpentasulfid in die Thiono-Derivate der Formel in welcher R1, R2, R3 und R4 die oben angegebenen Bedeutungen haben, überführt, und die resultierenden Verbindungen der Formel (I) gegebenenfalls mit den entsprechenden (i) Lösungsmitteln und/oder (ii) Basen oder Säuren zu ihren Solvaten, Salzen und/oder Solvaten der Salze umsetzt.
- 7
- 8Arzneimittel enthaltend mindestens eine der Verbindungen nach einem der Ansprüche 1 bis 5 und mindestens einen pharmazeutisch verträglichen, im wesentlichen nichtgiftigen Träger oder Exzipienten. Medicament comprising at least one of the compounds according to any of Claims 1 to 5 and at least one pharmaceutically acceptable, essentially nontoxic carrier or excipients. Médicaments contenant au moins l'un des composés selon l'une des revendications 1 à 5 et au moins un support ou excipient principalement non toxique, acceptable du point de vue pharmaceutique.
- 9Use of the compounds according to any of Claims 1 to 5 for producing a medicament for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory. Utilisation des composés suivant l'une des revendications 1 à 5 pour la préparation d'un médicament destiné à la prophylaxie et/ou au traitement de troubles de la perception, de la capacité de concentration, de la capacité d'apprentissage et/ou de la capacité de mémoire. Verwendung der Verbindungen nach einem der Ansprüche 1 bis 5 zur Herstellung eines Arzneimittels zur Prophylaxe und/oder Behandlung von Störungen der Wahrnehmung, Konzentrationsleistung, Lern- und/oder Gedächtnisleistung.
- 10Use according to Claim 9, wherein the impairment is a consequence of Alzheimer's disease. Utilisation suivant la revendication 9, le trouble étant une conséquence de la maladie d'Alzheimer. Verwendung nach Anspruch 9, wobei die Störung eine Folge der Alzheimer'schen Krankheit ist.
- 11Use of the compounds according to any of Claims 1 to 5 for producing a medicament for improving perception, concentration, learning and/or memory. Utilisation des composés suivant l'une des revendications 1 à 5 pour la préparation d'un médicament destiné à améliorer la perception, la capacité de concentration, la capacité d'apprentissage et/ou la capacité de mémoire. Verwendung der Verbindungen nach einem der Ansprüche 1 bis 5 zur Herstellung eines Arzneimittels zur Verbesserung der Wahrnehmung, Konzentrationsleistung, Lern- und/oder Gedächtnisleistung.
Independent claims11
203 paragraphs, as filed
The invention relates to new alkyl-substituted pyrazolopyrimidines, processes for their preparation, and their use for the production of medicaments for improving perception, concentration, learning and / or memory.
The cellular activation of adenylate or guanylate cyclases causes the cyclization of ATP or GTP to 5'-3 'cyclic adenosine monophosphate (cAMP) or 5'-3' cyclic guanosine monophosphate (cGMP). These cyclic nucleotides (cAMP and cGMP) are important second messengers and therefore play a central role in the cellular signal transduction cascades. Both reactivate, among other things, but not exclusively, protein kinases again. The protein kinase activated by cAMP is called protein kinase A (PKA), the protein kinase activated by cGMP is called protein kinase G (PKG). Activated PKA or PKG can in turn phosphorylate a number of cellular effector proteins (eg ion channels, G-protein coupled receptors, structural proteins). In this way, the second messengers cAMP and cGMP can control a wide variety of physiological processes in a wide variety of organs. The cyclic nucleotides can also act directly on effector molecules. For example, it is known that cGMP can act directly on ion channels and thus influence the cellular ion concentration (overview in: Wei et al.,<i>Prog. Neurobiol.,</i> 1998, <i>56</i>: 37-64). Phosphodiesterases (PDE) are a control mechanism to control the activity of cAMP and cGMP and thus these physiological processes. PDEs hydrolyze the cyclic monophosphates to the inactive monophosphates AMP and GMP. At least 21 PDE genes have now been described (<i>Exp. Opin. Investigious. Drugs</i> 2000, <i>9,</i> 1354-3784). These 21 PDE genes can be divided into 11 PDE families based on their sequence homology (nomenclature suggestion see http://depts.washington.edu/pde/Nomenclature.html.). Individual PDE genes within a family are distinguished by letters (eg PDE1A and PDE1B). If there are still different splice variants within a gene, this is then indicated by an additional numbering after the letter (eg PDE1A1).
The human PDE9A was cloned and sequenced in 1998. The amino acid identity to other PDEs is a maximum of 34% (PDE8A) and a minimum of 28% (PDE5A). With a Michaelis-Menten constant (Km value) of 170 nM, PDE9A is highly affine for cGMP. In addition, PDE9A is selective for cGMP (Km value for cAMP = 230 µM). PDE9A has no cGMP binding domain, which would suggest an allosteric enzyme regulation by cGMP. Western blot analysis showed that human PDE9A is expressed in the testes, brain, small intestine, skeletal muscles, heart, lungs, thymus and spleen. The highest expression was found in the brain, small intestine, heart and spleen (Fisher et al.,<i>J. Biol. Chem</i>., 1998, <i>273</i> (25): 15559-15564). The gene for human PDE9A is located on chromosome 21q22.3 and contains 21 exons. So far 4 alternative PDE9A splice variants have been identified (Guipponi et al.,<i>Hum. Genet</i>., 1998, <i>103</i>: 386-392). Classic PDE inhibitors do not inhibit human PDE9A. IBMX, Dipyridamole, SKF94120, Rolipram and Vinpocetin show no inhibition of the isolated enzyme in concentrations up to 100 µM. An IC was created for Zaprinast<sub>50</sub>Value of 35 µM detected (Fisher et al., <i>J. Biol. Chem.,</i> 1998, <i>273</i> (25): 15559-15564).
The mouse PDE9A was developed in 1998 by Soderling et al. (<i>J. Biol. Chem</i>., 1998, <i>273</i> (19): 15553-15558) cloned and sequenced. Like the human form, this is highly affine for cGMP with a Km of 70 nM. A particularly high expression in the kidney, brain, lungs and heart was found in the mouse. The mouse PDE9A is also not inhibited by IBMX in concentrations below 200 µM; the IC<sub>50</sub>Value for Zaprinast is 29 µM (Soderling et al., <i>J. Biol. Chem.,</i> 1998, <i>273</i> (19): 15553-15558). It has been shown in the rat brain that PDE9A is strongly expressed in some brain regions. These include the olfactory bulb, hippocampus, cortex, basal ganglia and basal forebrain (Andreeva et al.,<i>J. Neurosci</i>., 2001, <i>21</i> (22): 9068-9076). The hippocampus, cortex and basal forebrain in particular play an important role in learning and memory processes.
As already mentioned above, PDE9A is characterized by a particularly high affinity for cGMP. In contrast to PDE2A (Km = 10 µM; Martins et al.,<i>J. Biol. Chem</i>., 1982, <i>257</i>: 1973-1979), PDE5A (Km = 4 µM; Francis et al., <i>J. Biol. Chem</i>., 1980, <i>255</i>: 620-626), PDE6A (Km = 17 µM; Gillespie and Beavo, <i>J</i>. <i>Biol. Chem</i>., 1988, <i>263</i> (17): 8133-8141) and PDE11A (Km = 0.52 µM; Fawcett et al., <i>Proc. Nat. Acad. Sci</i>., 2000, 97 (7): 3702-3707) active even at low physiological concentrations. In contrast to PDE2A (Murashima et al.,<i>Biochemistry</i>, 1990, <i>29</i>: 5285-5292) the catalytic activity of PDE9A is not increased by cGMP, since it has no GAF domain (cGMP binding domain, via which the PDE activity is increased allosterically) (Beavo et al., <i>Current Opinion in Cell Biology,</i> 2000, <i>12</i>: 174-179). PDE9A inhibitors therefore lead to an increase in the basal cGMP concentration. This increase in basal cGMP concentration surprisingly led to an improvement in learning and memory performance in the Social Recognition Test.
WO 98/40384 discloses pyrazolopyrimidines which are distinguished as PDE1, 2 and 5 inhibitors and can be used for the treatment of cardiovascular and cerebrovascular diseases as well as diseases of the genitourinary region. Further pyrazolopyrimidines with PDE-inhibiting activity are disclosed in US 5,977,118 and EP 0 995 751.
CH 396 924, CH 396 925, CH 396 926, CH 396 927, DE 1 147 234, DE 1 149 013, GB 937,726 describe pyrazolopyrimidines with coronary-expanding activity which can be used for the treatment of circulatory disorders in the heart muscle.
No. 3,732,225 describes pyrazolopyrimidines which have an anti-inflammatory and blood sugar-lowering effect.
DE 2 408 906 describes styrene pyrazole pyrimidines which can be used as antimicrobial and anti-inflammatory agents for the treatment of, for example, edema.
The present invention relates to compounds of the formula<chemistry id="chem0001" num="0001"><img file="EP1534713B1_D0001.tif" /></chemistry>in which<dl id="dl0001" compact="compact"><dt>R<sup>1</sup></dt><dd>C.<sub>1</sub>-C<sub>6</sub>-Alkyl, trifluoromethyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-Alkoxy, -C (= O) OR<sup>5</sup> or -C (= O) NO<sup>6</sup>R<sup>7</sup>, where C<sub>1</sub>-C<sub>6</sub>-Alkyl optionally with 1 to 3 radicals independently selected from the group hydroxy, C<sub>1</sub>-C<sub>6</sub>-Alkoxy, halogen, trifluoromethyl, trifluoromethoxy, -C (= O) OR<sup>5</sup> or -C (= O) NO<sup>6</sup>R<sup>7</sup> is substituted, and R<sup>5</sup> for C<sub>1</sub>-C<sub>6</sub>-Alkyl, R<sup>6</sup> and R<sup>7</sup> independently for hydrogen, C<sub>6</sub>-C<sub>10</sub>-Aryl, C<sub>1</sub>-C<sub>6-</sub>Stand alkyl, or together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl,</dd><dt>R<sup>2</sup></dt><dd>Hydrogen, C<sub>1</sub>-C<sub>6</sub>-Alkyl, trifluoromethyl, C<sub>1</sub>-C<sub>6</sub>-Alkoxy,</dd></dl>or<dl id="dl0002" compact="compact"><dt>R<sup>1</sup> and R<sup>2</sup></dt><dd>together with the carbon atom to which they are attached, C<sub>3-</sub>C.<sub>8</sub>Cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-Cycloalkenyl or 4- to 10-membered heterocyclyl, optionally with up to 2 substituents from group C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>1</sub>-C<sub>6</sub>-Alkoxy, hydroxy, oxo, -C (= O) OR<sup>8</sup> are substituted, and R<sup>8</sup> for C<sub>1</sub>-C<sub>6</sub>Alkyl or benzyl,</dd><dt>R<sup>3</sup></dt><dd>Hydrogen or C<sub>1</sub>-C<sub>6</sub>-Alkyl,</dd><dt>R<sup>4</sup></dt><dd>Pentan-3-yl, C<sub>3</sub>-C<sub>6</sub>Cycloalkyl,</dd><dt>X</dt><dd>Oxygen or sulfur,</dd></dl>mean, and their salts, solvates and / or solvates of the salts.
Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts; the compounds of the formula (I) encompassed by the formulas mentioned below and their salts, solvates and solvates of the salts, and the compounds encompassed by the formula (I) hereinafter referred to as exemplary embodiments and their salts, solvates and solvates of the salts, insofar as the Compounds of formula (I) mentioned below are not already salts, solvates and solvates of the salts.
Depending on their structure, the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers). The invention therefore relates to the enantiomers or diastereomers and their respective mixtures. The stereoisomerically uniform constituents can be isolated in a known manner from such mixtures of enantiomers and / or diastereomers.
As <u style="single">Salts</u> Physiologically acceptable salts of the compounds according to the invention are preferred in the context of the invention.
Physiologically acceptable salts of the compounds (I) include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, Fumaric acid, maleic acid and benzoic acid.
Physiologically acceptable salts of the compounds (I) also include salts of conventional bases, such as, for example and preferably, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example Calcium and magnesium salts) and ammonium salts, derived from ammonia or organic amines with 1 to 16C atoms, such as, for example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, n-methylinoline, dibenzylamine, dibenzylamine , Dehydroabietylamine, arginine, lysine, ethylenediamine and methylpiperidine.
As <u style="single">Solvate</u> In the context of the invention, those forms of the compounds are referred to which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvate, in which coordination takes place with water.
The present disclosure also relates to prodrugs of the compounds according to the invention. The term “prodrugs” encompasses compounds which can themselves be biologically active or inactive, but are converted to compounds according to the invention (for example metabolically or hydrolytically) during their residence time in the body.
In the context of the present invention, unless otherwise specified, the substituents have the following meaning:<ul id="ul0001" list-style="none" compact="compact"><li><u style="single">C.</u><sub><u style="single">1</u></sub><u style="single">-C</u><sub><u style="single">6</u></sub><u style="single">-Alkoxy</u> represents a straight-chain or branched alkoxy radical having 1 to 6, preferably 1 to 4, particularly preferably having 1 to 3 carbon atoms. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.</li><li><u style="single">C.</u><sub><u style="single">1</u></sub><u style="single">-C</u><sub><u style="single">6</u></sub><u style="single">-Alkyl</u> represents a straight-chain or branched alkyl radical having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.</li><li><u style="single">C.</u><sub><u style="single">6</u></sub><u style="single">-C</u><sub><u style="single">10</u></sub><u style="single">-Aryl</u> stands for phenyl or naphthyl.</li><li><u style="single">C.</u><sub><u style="single">3</u></sub><u style="single">-C</u><sub><u style="single">8</u></sub><u style="single">Cycloalkyl</u> stands for cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, cycloheptyl or cyclooctyl. Cyclopropyl, cyclopentyl and cyclohexyl are preferred.</li><li><u style="single">C.</u><sub><u style="single">3</u></sub><u style="single">-C</u><sub><u style="single">8</u></sub><u style="single">-Cycloalkenyl</u> stands for partially unsaturated, non-aromatic cycloalkyl radicals which contain one or more multiple bonds, preferably double bonds. Non-limiting examples include cyclopentenyl, cyclohexenyl and cycloheptenyl.</li><li><u style="single">halogen</u> stands for fluorine, chlorine, bromine and iodine. Fluorine, chlorine, bromine are preferred, fluorine and chlorine are particularly preferred.</li><li><u style="single">4- to 10-membered heterocyclyl</u> represents a mono- or polycyclic, heterocyclic radical with 4 to 10 ring atoms and up to 3, preferably 1 heteroatoms or hetero groups from the series N, O, S, SO, SO<sub>2</sub>. 4- to 8-membered heterocyclyl is preferred. Mono- or bicyclic heterocyclyl is preferred. N and O are preferred as heteroatoms. The heterocyclyl residues can be saturated or partially unsaturated. Saturated heterocyclyl residues are preferred. The heterocyclyl radicals can be bonded via a carbon atom or a heteroatom. 5- to 7-membered, monocyclic saturated heterocyclyl radicals having up to two heteroatoms from the series O, N and S are particularly preferred. Examples and preferably mentioned are: oxetan-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolinyl, tetrahydrofuranyl, tetrahydrothienyl, pyranyl, piperidinyl, thiopyranyl, morpholinyl, perhydroazepinyl.</li></ul>
If radicals in the compounds according to the invention are optionally substituted, a substitution with up to three identical or different substituents is preferred, unless otherwise specified.
The compounds according to the invention can also be present as tautomers, as shown below by way of example:<chemistry id="chem0002" num="0002"><img file="EP1534713B1_D0002.tif" /></chemistry>
Another embodiment of the invention relates to compounds of formula (I), wherein<dl id="dl0003" compact="compact"><dt>R<sup>1</sup></dt><dd>C.<sub>1</sub>-C<sub>6</sub>-Alkyl, hydroxy, C<sub>1</sub>-C<sub>6</sub>-Alkoxy, -C (= O) OR<sup>5</sup> or -C (= O) NO<sup>6</sup>R<sup>7</sup>, where C<sub>1</sub>-C<sub>6</sub>-Alkyl optionally with hydroxy, C<sub>1</sub>-C<sub>6</sub>-Alkoxy, -C (= O) OR<sup>5</sup> or -C (= O) NO<sup>6</sup>R<sup>7</sup> is substituted, and R<sup>5</sup> for C<sub>1</sub>-C<sub>6</sub>-Alkyl, R<sup>6</sup> and R<sup>7</sup> independently for hydrogen, C<sub>6</sub>-C<sub>10</sub>-Aryl, C<sub>1</sub>-C<sub>6-</sub>Stand alkyl, or together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl,</dd><dt>R<sup>2</sup></dt><dd>Hydrogen, C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>1</sub>-C<sub>6</sub>-Alkoxy,</dd></dl>or<dl id="dl0004" compact="compact"><dt>R<sup>1</sup> and R<sup>2</sup></dt><dd>together with the carbon atom to which they are attached, C<sub>3-</sub>C.<sub>8</sub>Cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-Cycloalkenyl or 4- to 10-membered heterocyclyl, optionally with up to 2 substituents from group C<sub>1</sub>-C<sub>6</sub>-Alkyl, C<sub>1</sub>-C<sub>6</sub>-Alkoxy, hydroxy, oxo, -C (= O) OR<sup>8</sup> are substituted, and R<sup>8</sup> for C<sub>1</sub>-C<sub>6</sub>Alkyl or benzyl,</dd><dt>R<sup>3</sup></dt><dd>Hydrogen or C<sub>1</sub>-C<sub>6</sub>-Alkyl,</dd><dt>R<sup>4</sup></dt><dd>Pentan-3-yl, C<sub>4</sub>-C<sub>6</sub>Cycloalkyl,</dd><dt>X</dt><dd>Oxygen or sulfur,</dd></dl>mean, and their salts, solvates and / or solvates of the salts.
Another embodiment of the invention relates to compounds of formula (I), wherein<dl id="dl0005" compact="compact"><dt>R<sup>1</sup></dt><dd>C.<sub>1</sub>-C<sub>4</sub>-Alkyl, trifluoromethyl, hydroxy, C<sub>1</sub>-C<sub>4</sub>-Alkoxy, -C (= O) OR<sup>5</sup> or -C (= O) NO<sup>6</sup>R<sup>7</sup>, where C<sub>1</sub>-C<sub>4</sub>-Alkyl optionally with hydroxy, C<sub>1</sub>-C<sub>4-</sub>Alkoxy, trifluoromethyl, -C (= O) OR<sup>5</sup> or -C (= O) NO<sup>6</sup>R<sup>7</sup> is substituted, and R<sup>5</sup> for C<sub>1</sub>-C<sub>4</sub>-Alkyl, R<sup>6</sup> and R<sup>7</sup> independently for hydrogen, phenyl, C<sub>1</sub>-C<sub>4</sub>-Alkyl stand, or together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocyclyl,</dd><dt>R<sup>2</sup></dt><dd>Hydrogen, C<sub>1</sub>-C<sub>4</sub>-Alkyl, C<sub>1</sub>-C<sub>4</sub>-Alkoxy, trifluoromethyl,</dd></dl>or<dl id="dl0006" compact="compact"><dt>R<sup>1</sup> and R<sup>2</sup></dt><dd>together with the carbon atom to which they are attached, C<sub>5-</sub>C.<sub>6</sub>Cycloalkyl, C<sub>5</sub>-C<sub>6</sub>-Cycloalkenyl or 5- to 6-membered heterocyclyl, optionally with up to 2 substituents from group C<sub>1</sub>-C<sub>4</sub>-Alkyl, C<sub>1</sub>-C<sub>4</sub>-Alkoxy, hydroxy, oxo, -C (= O) OR<sup>8</sup> are substituted, and</dd><dt>R<sup>8</sup></dt><dd>for C<sub>1</sub>-C<sub>4</sub>Alkyl or benzyl,</dd><dt>R<sup>3</sup></dt><dd>Hydrogen,</dd><dt>R<sup>4</sup></dt><dd>Pentan-3-yl, C<sub>5</sub>-C<sub>6</sub>Cycloalkyl,</dd><dt>X</dt><dd>Oxygen or sulfur,</dd></dl>mean, and their salts, solvates and / or solvates of the salts.
Another embodiment of the invention relates to compounds of formula (I), wherein<dl id="dl0007" compact="compact"><dt>R<sup>1</sup></dt><dd>Methyl, ethyl, isopropyl, trifluoromethyl, methoxycarbonyl, ethoxycarbonyl or -C (= O) NR<sup>6</sup>R<sup>7</sup>, where methyl is optionally substituted by methoxycarbonyl or ethoxycarbonyl, and R<sup>6</sup> stands for phenyl and R<sup>7</sup> represents hydrogen,</dd><dt>R<sup>2</sup></dt><dd>Hydrogen, methyl, trifluoromethyl, or</dd><dt>R<sup>1</sup> and R<sup>2</sup></dt><dd>together with the carbon atom to which they are attached form cyclopentyl, cyclohexyl, cyclopentenyl or tetrahydrofuryl, cyclohexyl optionally being substituted by methyl, and</dd><dt>R<sup>3</sup></dt><dd>Hydrogen,</dd><dt>R<sup>4</sup></dt><dd>Pentan-3-yl, C<sub>5</sub>-C<sub>6</sub>Cycloalkyl,</dd><dt>X</dt><dd>Oxygen or sulfur,</dd></dl>mean, and their salts, solvates and / or solvates of the salts.
Another embodiment of the invention relates to compounds of formula (I), wherein<dl id="dl0008" compact="compact"><dt>R<sup>1</sup></dt><dd>Methyl, ethyl, isopropyl, methoxycarbonyl, ethoxycarbonyl or -C (= O) NR<sup>6</sup>R<sup>7</sup>, where methyl is optionally substituted by methoxycarbonyl or ethoxycarbonyl, and R<sup>6</sup> stands for phenyl and R<sup>7</sup> stand for hydrogen,</dd><dt>R<sup>2</sup></dt><dd>Hydrogen, methyl, or</dd><dt>R<sup>1</sup> and R<sup>2</sup></dt><dd>together with the carbon atom to which they are attached form cyclopentyl, cyclohexyl, cyclopentenyl or tetrahydrofuryl, cyclohexyl optionally being substituted by methyl, and</dd><dt>R<sup>3</sup></dt><dd>Hydrogen,</dd><dt>R<sup>4</sup></dt><dd>Pentan-3-yl, C<sub>5</sub>-C<sub>6</sub>Cycloalkyl,</dd><dt>X</dt><dd>Oxygen,</dd></dl>mean, and their salts, solvates and / or solvates of the salts.
In addition, a process for the preparation of the compounds of the formula (I) according to the invention was found, characterized in that either<ul id="ul0002" list-style="none" compact="compact"><li>[A] Compounds of the formula<chemistry id="chem0003" num="0003"><img file="EP1534713B1_D0003.tif" /></chemistry>in which R<sup>4</sup> has the meanings given above, by reaction with a compound of the formula<chemistry id="chem0004" num="0004"><img file="EP1534713B1_D0004.tif" /></chemistry>in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the meanings given above, and<dl id="dl0009" compact="compact"><dt>Z.</dt><dd>represents chlorine or bromine,</dd></dl>in an inert solvent and in the presence of a base, first in compounds of the formula<chemistry id="chem0005" num="0005"><img file="EP1534713B1_D0005.tif" /></chemistry>in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings given above, transferred, then in an inert solvent in the presence of a base to compounds of the formula<chemistry id="chem0006" num="0006"><img file="EP1534713B1_D0006.tif" /></chemistry>in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings given above, cyclized, or</li><li>[B] Compounds of formula (II) with direct cyclization to (IA) with a compound of formula<chemistry id="chem0007" num="0007"><img file="EP1534713B1_D0007.tif" /></chemistry>in which R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the meanings given above and<dl id="dl0010" compact="compact"><dt>R<sup>9</sup></dt><dd>represents methyl or ethyl,</dd></dl>reacted in an inert solvent and in the presence of a base, or</li><li>[C] Compounds of the formula<chemistry id="chem0008" num="0008"><img file="EP1534713B1_D0008.tif" /></chemistry>in which R<sup>4</sup> has the meanings given above, initially by reaction with a compound of the formula (IIIa) in an inert solvent and in the presence of a base in compounds of the formula<chemistry id="chem0009" num="0009"><img file="EP1534713B1_D0009.tif" /></chemistry>in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings given above, convicted, and in a second step cyclizes them to (IA) in an inert solvent and in the presence of a base and an oxidizing agent,</li></ul>and the compounds of the formula (IA) then, if appropriate, by reaction with a sulfurizing agent such as, for example, diphosphorus pentasulfide, in the thiono derivatives of the formula<chemistry id="chem0010" num="0010"><img file="EP1534713B1_D0010.tif" /></chemistry>in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings given above, convicted, and optionally reacting the resulting compounds of the formula (I) with the corresponding (i) solvents and / or (ii) bases or acids to give their solvates, salts and / or solvates of the salts.
Inert organic solvents which do not change under the reaction conditions are suitable for the first step of process [A] and process [C]. These preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran or glycol dimethyl ether, or toluene or pyridine. It is also possible to use mixtures of the solvents mentioned. Tetrahydrofuran, toluene or pyridine are particularly preferred.
Suitable bases are generally alkali metal hydrides, such as sodium hydride, or cyclic amines, such as piperidine, pyridine, dimethylaminopyridine (DMAP), or C.<sub>1</sub>-C<sub>4</sub>Alkylamines, such as triethylamine. Sodium hydride, pyridine and / or dimethylaminopyridine are preferred.
The base is generally used in an amount of 1 mol to 4 mol, preferably from 1.2 mol to 3 mol, in each case based on 1 mol of the compounds of the general formula (II) or (V).
In a variant, the reaction is carried out in pyridine, to which a catalytic amount of DMAP is added. If necessary, toluene can also be added.
The reaction temperature can generally be varied within a substantial range. Generally one works in a range from -20 ° C to + 200 ° C, preferably from 0 ° C to + 100 ° C.
The usual organic solvents are suitable as solvents for the cyclization in the second step of processes [A] and [C]. These preferably include alcohols such as methanol, ethanol, propanol, isopropanol, n-butanol or tert-butanol, or ethers such as tetrahydrofuran or dioxane, or dimethylformamide or dimethyl sulfoxide. Alcohols such as methanol, ethanol, propanol, isopropanol or tert-butanol are particularly preferably used. It is also possible to use mixtures of the solvents mentioned.
The usual inorganic bases are suitable as bases for the cyclization in the second step of processes [A] and [C]. These preferably include alkali metal hydroxides or alkaline earth metal hydroxides such as sodium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates such as sodium or potassium carbonate or sodium hydrogen carbonate, or alkali metal alcoholates such as sodium methoxide, sodium ethanolate, potassium methoxide, potassium ethanolate or potassium tert-butoxide. Potassium carbonate, sodium hydroxide and potassium tert-butoxide are particularly preferred.
When carrying out the cyclization, the base is generally used in an amount of from 2 mol to 6 mol, preferably from 3 mol to 5 mol, in each case based on 1 mol of the compounds of the general formula (IV) or (VI).
Suitable oxidants for the cyclization in the second step of process [C] are, for example, hydrogen peroxide or sodium borate. Hydrogen peroxide is preferred.
The cyclization in processes [A], [B] and [C] is generally carried out in a temperature range from 0 ° C. to + 160 ° C., preferably at the boiling point of the particular solvent.
The cyclization is generally carried out at normal pressure. However, it is also possible to carry out the process under overpressure or under underpressure (for example in a range from 0.5 to 5 bar).
Suitable solvents for process [B] are the alcohols listed above for the second step of processes [A] and [C], ethanol being preferred.
Suitable bases for the process [B] are alkali metal hydrides, such as sodium or potassium hydride, or alkali metal alcoholates, such as sodium methoxide, ethanolate, isopropoxide or potassium tert-butoxide. Sodium hydride is preferred.
The base is used in an amount of 2 mol to 8 mol, preferably 3 mol to 6 mol, in each case based on 1 mol of the compounds of the formula (II).
The compounds of the formula (II) are known or can be prepared, for example, by first treating ethoxymethylene malononitrile with hydrazine derivatives of the formula (VII) R<sup>4</sup>-NH-NH<sub>2</sub> (VII), in which R<sup>4</sup> has the meanings given above, condensed in an inert solvent to give the pyrazole nitriles of the formula (V) and then reacting them with one of the oxidizing agents listed above, preferably hydrogen peroxide, in the presence of ammonia [cf. eg A. Miyashita et al., Heterocycles 1990, 31, 1309ff].
The compounds of the formulas (IIIa), (IIIb) and (VII) are commercially available, known from the literature or can be prepared analogously to processes known from the literature.
The process according to the invention can be illustrated by the following formula scheme:<chemistry id="chem0011" num="0011"><img file="EP1534713B1_D0011.tif" /></chemistry>
Compounds of the formula (IA) and (IB) may optionally be within the scope of R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> be further modified according to standard procedures.
Other processes for the preparation of pyrazolo [3,4-d] pyrimidin-4-ones are known and can also be used for the synthesis of the compounds according to the invention (see for example: P. Schmidt et al., Helvetica Chimica Acta 1962, <i>189</i>, 1620ff.).
The compounds according to the invention show an unforeseeable, valuable pharmacological and pharmacokinetic spectrum of action.
They are therefore suitable for use as medicaments for the treatment and / or prophylaxis of diseases in humans and animals.
The term "treatment" in the context of the present invention includes prophylaxis.
Surprisingly, it was found that selective PDE9A inhibitors are suitable for the production of medicaments for improving perception, concentration performance, learning performance or memory performance.
Because of their pharmacological properties, the compounds according to the invention can be used alone or in combination with other medicaments to improve perception, concentration, learning and / or memory.
The present disclosure furthermore relates to a method for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases, using an effective amount of the compounds according to the invention.
A <u style="single">PDE9A inhibitor</u> For the purposes of the invention, a compound is the human PDE9A under the conditions specified below with an IC<sub>50</sub>Inhibits a value of less than 10 µM, preferably less than 1 µM.
A <u style="single">more selective</u> PDE9A inhibitor in the sense of the invention is a compound which more effectively inhibits human PDE9A under the conditions specified below than the human PDE1C, PDE2A, PDE3B, PDE4B, PDE5A, PDE7B, PDE8A, PDE10A and PDE11. A ratio of IC is preferred<sub>50</sub> (PDE9A) / IC<sub>50</sub> (PDE1C, PDE2A, PDE3B, PDE4B, PDE5A, PDE7B and PDE10A) less than 0.2.
The selective PDE9A inhibitors are particularly suitable for improving perception, concentration performance, learning performance, or memory performance after cognitive disorders, as they occur in particular in situations / diseases / syndromes such as "mild cognitive impairment", age-associated learning and memory disorders, age-associated memory loss, vascular Dementia, traumatic brain injury, stroke, dementia that occurs after stroke ("post stroke dementia"), post-traumatic dementia, general concentration disorders, concentration disorders in children with learning and memory problems, Alzheimer's disease, dementia with Lewy bodies, dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal Degeneration, amyotropic lateral sclerosis (ALS), Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, Schizophrenia with dementia or Korsakoff psychosis.
The <i>in vitro</i>Effect of the compounds according to the invention can be shown with the following biological assays:
<u style="single">PDE inhibition</u>
Recombinant PDE1C (GenBank / EMBL Accession Number: NM_005020, Loughney et al. <i>J. Biol. Chem.</i> 1996 <i>271,</i> 796-806), PDE2A (GenBank / EMBL Accession Number: NM_002599, Rosman et al. <i>Genes</i> 1997 <i>191,</i> 89-95), PDE3B (GenBank / EMBL Accession Number: NM_000922, Miki et al. <i>Genomics</i> 1996, <i>36,</i> 476-485), PDE4B (GenBank / EMBL Accession Number: NM_002600, Obemolte et al. <i>Genes.</i> 1993, <i>129,</i> 239-247), PDE5A (GenBank / EMBL Accession Number: NM_001083, Loughney et al. <i>Genes</i> 1998, <i>216</i>, 139-147), PDE7B (GenBank / EMBL Accession Number: NM_018945, Hetman et al. <i>Proc. Natl. Acad Sci. United States</i> 2000, <i>97</i>, 472-476), PDE8A (GenBank / EMBL Accession Number: AF_056490, Fisher et al. <i>Biochem. Biophys. Res. Commun.</i> 1998 246, 570-577), PDE9A (Fisher et al., J. Biol. Chem, 1998, 273 (25): 15559-15564), PDE10A (GenBank / EMBL Accession Number: NM_06661, Fujishige et al. <i>J Biol Chem</i>. 1999, <i>274</i>, 18438-45.), PDE11A (GenBank / EMBL Accession Number: NM_016953, Fawcett et al. <i>Proc. Natl. Acad. Sci</i>. 2000, <i>97</i>, 3702-3707) were expressed using the pFASTBAC baculovirus expression system (GibcoBRL) in Sf9 cells.
The test substances are used to determine their <i>in vitro</i> Effect on PDE 9A dissolved in 100% DMSO and serially diluted. Typically, dilution series from 200 µM to 1.6 µM are produced (resulting final concentrations in the test: 4 µM to 0.032 µM). In each case 2 μL of the diluted substance solutions are placed in the wells of microtiter plates (Isoplate; Wallac Inc., Atlanta, GA). Then 50 µL of a dilution of the PDE9A preparation described above are added. The dilution of the PDE9A preparation is chosen so that less than 70% of the substrate is converted during the later incubation (typical dilution: 1: 10000; dilution buffer: 50 mM Tris / HCl pH 7.5, 8.3 mM MgCl<sub>2</sub>, 1.7 mM EDTA, 0.2% BSA). The substrate, [8-<sup>3</sup>H] guanosine 3 ', 5'-cyclic phosphate (1 µCi / µL; Amersham Pharmacia Biotech., Piscataway, NJ) is 1: 2000 with assay buffer (50 mM Tris / HCl pH 7.5, 8.3 mM MgCl<sub>2</sub>, 1.7 mM EDTA) diluted to a concentration of 0.0005 µCi / µL. The enzyme reaction is finally started by adding 50 µL (0.025 µCi) of the diluted substrate. The test batches are incubated for 60 min at room temperature and the reaction is stopped by adding 25 μl of a PDE9A inhibitor dissolved in assay buffer (for example the inhibitor from preparation example 1, 10 μM final concentration). 25 µL of a suspension with 18 mg / mL yttrium scintillation proximity beads (Amersham Pharmacia Biotech., Piscataway, NJ) are added immediately afterwards. The microtiter plates are sealed with a film and left to stand at room temperature for 60 min. The plates are then measured for 30 s per well in a Microbeta scintillation counter (Wallac Inc., Atlanta, GA). IC<sub>50-</sub>Values are determined on the basis of the graphical plot of the substance concentration against the percentage inhibition.
The <i>in vitro</i> Effect of test substances on recombinant PDE3B, PDE4B, PDE7B, PDE8A, PDE10A and PDE11A is determined according to the test protocol described above for PDE 9A with the following adjustments: [5 ', 8-<sup>3</sup>H] adenosine 3 ', 5'-cyclic phosphate (1 µCi / µL; Amersham Pharmacia Biotech., Piscataway, NJ). It is not necessary to add an inhibitor solution to stop the reaction. Instead, following the incubation of substrate and PDE, the addition of the yttrium scintillation proximity beads is continued as described above and the reaction is thereby stopped. In order to determine a corresponding effect on recombinant PDE1C, PDE2A and PDE5A, the protocol is also adapted as follows: With PDE1C, Calmodulin 10 is also used<sup>-7</sup> M and CaCl<sub>2</sub> 3 mM added to the reaction mixture. PDE2A is stimulated in the test by adding cGMP 1 µM and tested with a BSA concentration of 0.01%. For PDE1C and PDE2A, the substrate [5 ', 8-<sup>3</sup>H] adenosine 3 ', 5'-cyclic phosphate (1 µCi / µL; Amersham Pharmacia Biotech., Piscataway, NJ), for PDE5A [8-<sup>3</sup>H] guanosine 3 ', 5'-cyclic phosphate (1 µCi / µL; Amersham Pharmacia Biotech., Piscataway, NJ).
The PDE9A-inhibiting activity of the compounds according to the invention can be shown using the following examples in Tables 1 and 2:<tables id="tabl0001" num="0001"><table frame="all"><title><u style="single">Table 1</u>: Inhibition of PDE isoenzymes by Example 3</title><tgroup cols="3" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="55mm" colsep="1" /><colspec colnum="2" colname="col2" colwidth="18mm" colsep="1" /><colspec colnum="3" colname="col3" colwidth="19mm" colsep="1" /><thead><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>Isoenzyme</b></entry><entry namest="col2" nameend="col2" align="left" valign="top"><b>Species</b></entry><entry namest="col3" nameend="col3" align="left" valign="top"><b>IC</b><sub><b>50</b></sub><b>[nM]</b></entry></row></thead><tbody><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE1C</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">720</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE2A</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">> 4000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE3B</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">> 4000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE4B</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">> 4000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE5A</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">> 4000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE7B</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">> 4000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE8A</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">> 4000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE9A</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">110</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">PDE10A</entry><entry namest="col2" nameend="col2" align="left" valign="top">human</entry><entry namest="col3" nameend="col3" align="left" valign="top">> 4000</entry></row></tbody></tgroup></table></tables><tables id="tabl0002" num="0002"><table frame="all"><title><u style="single">Table 2:</u> PDE9A inhibitory activity of the compounds according to the invention</title><tgroup cols="2" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="96mm" colsep="1" /><colspec colnum="2" colname="col2" colwidth="20mm" colsep="1" /><thead><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>example</b></entry><entry namest="col2" nameend="col2" align="left" valign="top"><b>IC</b><sub><b>50</b></sub><b>[nM]</b></entry></row></thead><tbody><row><entry namest="col1" nameend="col1" align="left" valign="top">1</entry><entry namest="col2" nameend="col2" align="left" valign="top">5</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">3</entry><entry namest="col2" nameend="col2" align="left" valign="top">110</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">4</entry><entry namest="col2" nameend="col2" align="left" valign="top">30</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">6</entry><entry namest="col2" nameend="col2" align="left" valign="top">6</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">12</entry><entry namest="col2" nameend="col2" align="left" valign="top">65</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">17</entry><entry namest="col2" nameend="col2" align="left" valign="top">86</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">19</entry><entry namest="col2" nameend="col2" align="left" valign="top">390</entry></row></tbody></tgroup></table></tables>
<u style="single">Increase in intracellular neuronal cGMP concentration in cell cultures</u>
PDE9A inhibitors increase intracellular neuronal cGMP in cultured primary cortical neurons.
Rat embryos (embryonic day E17 - E19) were decapitated and the heads were transferred to preparation trays filled with preparation medium (DMEM, penicillin / streptomycin; both from Gibco). The scalp and cranium were removed and the free brains were transferred to another Petri dish containing preparation medium. The cerebrum (cortex) was isolated using a binocular and two forceps and cooled to 4 ° C with ice. This preparation and the separation of the cortical neurons were then carried out according to a standard protocol using the papain kit (Worthington Biochemical Corporation, Lakewood, New Jersey 08701, USA) (Huettner et al. <i>J. Neurosci.</i> 1986, <i>6</i>, 3044-3060). The mechanically isolated cortical neurons were 150,000 cells / hole in 200 µl neurobasal medium / hole (neurobasal; B27 supplement; 2 mM L-glutamine; in the presence of penicillin / streptomycin; all agents from Gibco) 7 days in 96 perforated plates (with poly D-lysine 100 µg / ml pretreated for 30 min) cultivated under standard conditions (37 ° C, 5% CO<sub>2</sub>). After 7 days, the medium was removed and the cells were washed with HBSS buffer (Hank's balanced salt solution, Gibco / BRL). 100 μl of the compound according to the invention are then dissolved in HBSS buffer (previously dissolved in 100% DMSO: 10 mM) and applied to the cells. Then another 100 μl HBSS buffer are added so that the final concentration of the compounds according to the invention is, for example, in a range from 20 nM to 10 μM, and incubated at 37 ° C. for 20 min. The test buffer is then completely removed. The cells are then lysed in 200 μl lysis buffer (cGMP kit code RPN 226; from Amersham Pharmacia Biotech.) And the cGMP concentration is measured according to the manufacturer's instructions. All measurements are carried out in triplicate. The statistical evaluation is carried out with Prism Software Version 2.0 (GraphPad Software Inc., San Diego, CA USA).
Incubation of the primary neurons with the compounds according to the invention led to an increase in the cGMP content.
<u style="single">Long-term potentiation</u>
Long-term potentiation is seen as a cellular correlate for learning and memory processes. The following method can be used to determine whether PDE9 inhibition has an effect on long-term potentiation:
Rat hippocampi are placed at an angle of approximately 70 degrees in relation to the cutting blade (chopper). The hippocampus is cut at intervals of 400 µm. The sections are removed from the blade using a very soft, heavily wetted brush (marten hair) and placed in a glass vessel with carbogenized, cooled nutrient solution (124 mM NaCl, 4.9 mM KCl, 1.3 mM MgSO 4<sub>4</sub> x 7H<sub>2</sub>O, 2.5 mM CaCl<sub>2</sub> anhydrous, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 25.6 mM NaHCO<sub>3</sub>, 10 mM glucose, pH 7.4). During the measurement, the sections are in a temperature-controlled chamber under a liquid level of 1-3 mm in height. The flow rate is 2.5 ml / min. Pre-gassing takes place under slight excess pressure (about 1 atm) and via a micro-cannula in the antechamber. The cutting chamber is connected to the antechamber so that mini circulation can be maintained. The carbogen flowing out through the microcannula is used to drive the mini-circulation. The freshly prepared hippocampal slices are adapted at least 1 hour at 33 ° C in the cutting chamber.
The stimulus strength is chosen so that the focal excitative post-synaptic potential (fEPSP) is 30% of the maximum excitatory post-synaptic potential (EPSP). The Schaffer collaterals are locally excited (voltage: 1-5 V, pulse width of a polarity 0.1 ms, total pulse 0.2 ms) with the help of a monopolar stimulation electrode, which is made of painted stainless steel, and a current-constant, biphasic stimulus generator (AM-Systems 2100). With the help of glass electrodes (borosilicate glass with filament, 1-5 MOhm, diameter: 1.5 mm, tip diameter: 3-20 µm), which are filled with normal nutrient solution, the excitatory postsynaptic potential (fEPSP) is registered from the stratum radiatum. The field potentials are measured using a chlorinated silver reference electrode, which is located at the edge of the cutting chamber, with the help of a DC voltage amplifier. The field potentials are filtered using a low-pass filter (5 kHz). For the statistical analysis of the experiments, the slope of the fEPSPs (fEPSP rise) is determined. The experiment is recorded, analyzed and controlled using a software program (PWIN), which was developed in the Neurophysiology department. The averaging of the fEPSP rise values at the respective times and the construction of the diagrams are carried out with the help of the EXCEL software, whereby a corresponding macro automates the recording of the data.
Superfusion of the hippocampal sections with a 10 μM solution of the compounds according to the invention leads to a significant increase in the LTP.
<u style="single">Social recognition test:</u>
The social recognition test is a learning and memory test. It measures the ability of rats to distinguish between known and unknown species. This test is therefore suitable for testing the learning or memory-improving effect of the compounds according to the invention.
Adult rats that are kept in groups are placed individually in test cages 30 minutes before the start of the test. The test animal is placed in an observation box four minutes before the start of the test. After this adaptation time, a juvenile animal is added to the test animal and the absolute time that the adult animal inspects the cub is measured for 2 minutes (Trial 1). All behaviors clearly aimed at the young animal are measured, ie ano-genital inspection, tracking and grooming, in which the old animal had a maximum distance of 1 cm from the young animal. The juvenile is then removed, the adult treated with a compound or vehicle according to the invention and then returned to its home cage. After a retention time of 24 hours, the test is repeated (Trial 2). A reduced social interaction time compared to Trial 1 indicates that the adult rat remembers the cub.
The adult animals are directly after trial 1 either with vehicle (10% ethanol, 20% Solutol, 70% physiological saline) or 0.1 mg / kg, 0.3 mg / kg, 1.0 mg / kg or 3.0 mg / kg compound according to the invention , dissolved in 10% ethanol, 20% Solutol, 70% physiological saline injected intraperitoneally. Vehicle-treated rats show no reduction in social interaction time in Trial 2 compared to Trial 1. As a result, they have forgotten that they have had contact with the young animal before. Surprisingly, the social interaction time in the second round after treatment with the compounds according to the invention is significantly reduced compared to the vehicle treated. This means that the substance-treated rats have remembered the juvenile animal and thus the compounds according to the invention have an improving effect on learning and memory.
The present invention furthermore relates to medicaments containing at least one compound according to the invention and at least one or more further active substances, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
The compounds according to the invention can act systemically and / or locally. For this purpose, they can be applied in a suitable manner, such as, for example, orally, parenterally, pulmonally, nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, otically or as an implant or stent.
For these administration routes, the compounds according to the invention can be administered in suitable administration forms.
For oral administration, state-of-the-art, fast and / or modified application forms which release the compounds according to the invention and contain the compounds according to the invention in crystalline and / or amorphized and / or dissolved form, such as, for example, are suitable Tablets (non-coated or coated tablets, for example with gastric juice-resistant or delayed dissolving or insoluble coatings which control the release of the compound according to the invention), rapidly disintegrating tablets or films / wafers, films / lyophilisates, capsules (for example hard or Soft gelatin capsules), coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
Parenteral administration can be done bypassing a resorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbally) or by switching on absorption (e.g. intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). Suitable forms of application for parenteral administration include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
For the other application routes, inhalation drug forms (among others Powder inhalers, nebulizers), nose drops, solutions, sprays; tablets, films / wafers or capsules to be applied lingually, sublingually or buccally, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shaking mixes), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (such as plasters), milk, Pastes, foams, scattering powder, implants or stents.
The compounds according to the invention can be converted into the administration forms mentioned. This can be done in a manner known per se by mixing with inert, non-toxic, pharmaceutically suitable auxiliaries. These auxiliaries include carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (e.g. sodium dodecyl sulfate, polyoxysorbitanoleate), binders (e.g. polyvinylpyrrolidone), synthetic and natural polymers (e.g. albumin), stabilizers (e.g. antioxidants such as ascorbic acid), dyes (e.g. inorganic pigments such as iron oxides) and taste and / or smell.
The present invention further relates to medicaments which contain at least one compound according to the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable auxiliaries, and to their use for the purposes mentioned above.
In general, it has proven to be advantageous to administer amounts of approximately 0.001 to 10 mg / kg of body weight per day in the case of parenteral administration in order to achieve effective results. With oral administration, the amount per day is about 0.005 to 3 mg / kg body weight.
Nevertheless, it may be necessary to deviate from the amounts mentioned, depending on body weight, route of administration, individual behavior towards the active ingredient, type of preparation and time or interval at which the application is carried out. In some cases it may be sufficient to make do with less than the aforementioned minimum quantity, while in other cases the above upper limit must be exceeded. In the case of application of larger quantities, it may be advisable to distribute them in several single doses over the day.
The percentages in the following tests and examples are, unless stated otherwise, percentages by weight; Parts are parts by weight. Solvent ratios, dilution ratios and concentration details of liquid / liquid solutions each relate to the volume.
<u style="single">Used abbreviations:</u>
<dl id="dl0011" compact="compact"><dt>BSA</dt><dd>Bovine Serum Albumin</dd><dt>DCI</dt><dd>direct chemical ionization (for MS)</dd><dt>DMSO</dt><dd>Dimethyl sulfoxide</dd><dt>i.e. the</dt><dd>the theory (with yield)</dd><dt>EDTA</dt><dd>Ethylenediaminetetraacetic acid</dd><dt>equiv.</dt><dd>Equivalent (s)</dd><dt>IT I</dt><dd>Electrospray ionization (for MS)</dd><dt>HATU</dt><dd><i>O</i>- (7-Azabenzotriazol-1-yl) -<i>N</i>,<i>N</i>,<i>N</i>',<i>N</i>'tetramethyluronium hexafluorophosphate</dd><dt>Lit.</dt><dd>Literature (position)</dd><dt>MS</dt><dd>Mass spectroscopy</dd><dt>NMR</dt><dd>Nuclear magnetic resonance spectroscopy</dd><dt>M.p.</dt><dd>Melting point</dd><dt>Tris</dt><dd>Tris (hydroxymethyl) aminomethane</dd></dl>
<u style="single">Output connections:</u>
<u style="single">Example 1A</u>
5-amino-1-cyclohexyl-1H-pyrazole-4-carbonitrile
<chemistry id="chem0012" num="0012"><img file="EP1534713B1_D0012.tif" /></chemistry>
A solution of cyclohexylhydrazine hydrochloride (3 g, 19.9 mmol) in 36 ml of ethanol is first mixed at room temperature with ethoxymethylene malononitrile (2.43 g, 19.9 mmol) and then with 8 ml of triethylamine. The mixture is refluxed for 20 minutes and then cooled. The solvent is removed on a rotary evaporator and the residue is taken up in DCM, washed with aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated in vacuo. The crude product is chromatographed on silica gel (mobile phase: dichloromethane / methanol 0-10%). Yield: 1.95 g (51% of theory) MS (DCI): m / z = 191 (M + H)<sup>+</sup><sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 7.5 (s, 1H), 6.5 (s, 2H), 4.0 (m, 1H), 1.95-1.05 (m, 10H) ppm.
<u style="single">Example 2A</u>
5-amino-1-cyclopentyl-1H-pyrazole-4-carbonitrile
<chemistry id="chem0013" num="0013"><img file="EP1534713B1_D0013.tif" /></chemistry>
The preparation is carried out analogously to the instructions for Example 1A. MS (ESI): m / z = 177 (M + H)<sup>+</sup><sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): δ = 7.5 (s, 1H), 4.45 (br. s, 2H), 4.35 (m, 1H), 2.2-1.55 (m, 6H) ppm.
<u style="single">Example 3A</u>
5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carbonitrile
<chemistry id="chem0014" num="0014"><img file="EP1534713B1_D0014.tif" /></chemistry>
The preparation is carried out analogously to the instructions for Example 1A. MS (ESI): m / z = 179 (M + H)<sup>+</sup><sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 7.55 (s, 1H), 6.45 (s, 2H), 4.0 (m, 1H), 1.8-1.55 (m, 4H), 0.65 (t, 6H) ppm.
<u style="single">Example 4A</u>
5-amino-1-cyclohexyl-1H-pyrazole-4-carboxamide
<chemistry id="chem0015" num="0015"><img file="EP1534713B1_D0015.tif" /></chemistry>
A solution of 5-amino-1-cyclohexyl-1H-pyrazole-4-carbonitrile (1.86 g, 9.81 mmol) in a mixture of 73 ml of ethanol and 90 ml of concentrated aqueous ammonia solution is mixed with 18 ml of 30% hydrogen peroxide solution at room temperature and stirred for 1 h at room temperature. The non-aqueous solvents are then removed on the rotary evaporator. The product precipitates from the remaining mixture as a solid, which is filtered off with suction, washed with a little water and dried in a high vacuum. Yield: 1.77 g (86% of theory) MS (DCI): m / z = 209 (M + H)<sup>+</sup><sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 7.6 (s, 1H), 7.3-6.4 (broad, 2H), 6.1 (s, 2H), 3.95 (m, 1H), 1.95-1.05 (m, 10H) ppm.
<u style="single">Example 5A</u>
5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide
<chemistry id="chem0016" num="0016"><img file="EP1534713B1_D0016.tif" /></chemistry>
The preparation is carried out analogously to the instructions for Example 4A. MS (ESI): m / z = 195 (M + H)<sup>+</sup><sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): δ = 7.5 (s, 1H), 5.6-4.8 (broad, 4H), 4.35 (m, 1H), 2.2-1.55 (m, 8H) ppm.
<u style="single">Example 6A</u>
5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide
<chemistry id="chem0017" num="0017"><img file="EP1534713B1_D0017.tif" /></chemistry>
The preparation is carried out analogously to the instructions for Example 4A. MS (ESI): m / z = 197 (M + H)<sup>+</sup><sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 7.65 (s, 1H), 6.9 (br. s, 2H), 6.1 (s, 2H), 3.9 (m, 1H), 1.85-1.6 (m, 4H), 0.7 (t, 6H) ppm .
<u style="single">Examples:</u>
<u style="single">example 1</u>
6- (Cyclohexylmethyl) -1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0018" num="0018"><img file="EP1534713B1_D0018.tif" /></chemistry>
75 mg (0.39 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide and 183 mg (1.16 mmol, 3 equiv.) Of methyl cyclohexylacetate in 1.5 ml of absolute ethanol are introduced under argon. At 0 ° C, 54 mg sodium hydride (60% dispersion in mineral oil; 1.35 mmol, 3.5 equiv.) Are slowly added in counter-argon flow. The resulting mixture is slowly warmed and stirred under reflux for 18 h. For working up, 20 ml of water are added and the mixture is extracted several times with ethyl acetate. The combined organic phases are dried over sodium sulfate and concentrated in vacuo. The crude product is purified using preparative HPLC. Yield: 36 mg (31% of theory) MS (ESI): m / z = 301 (M + H)<sup>+</sup>M.p .: 147 ° C<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 11.95 (s, 1H), 8.0 (s, 1H), 5.1 (m, 1H), 2.5 (d, 2H), 2.15-1.75 (m, 7H), 1.75-1.55 (m, 7H), 1.3-0.9 (m, 5H) ppm.
<u style="single">Example 2</u>
1-Cyclopentyl-6- (3-hydroxypropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0019" num="0019"><img file="EP1534713B1_D0019.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 75 mg (0.39 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide and 140 mg (1.16 mmol) of 4-hydroxybutyric acid methyl ester. Yield: 85 mg (84% of theory) MS (DCI): m / z = 263 (M + H)<sup>+</sup>M.p .: 138 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 8.0 (s, 1H), 5.1 (m, 1H), 3.5 (t, 2H, <i>J =</i> 6.5 Hz), 2.65 (t, 2H, <i>J</i> = 7.5 Hz), 2.2-1.55 (m, 10H) ppm.
<u style="single">Example 3</u>
6- (Cyclohexylmethyl) -1- (1-ethylpropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0020" num="0020"><img file="EP1534713B1_D0020.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.02 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 482 mg (3.06 mmol) of methyl cyclohexylacetate. Yield: 146 mg (47% of theory) MS (ESI): m / z = 303 (M + H)<sup>+</sup>M.p .: 122 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.45 (m, 1H), 2.5 (m, 2H), 2.0-1.5 (m, 10H), 1.4-0.9 (m, 5H), 0.6 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 4</u>
1-Cyclopentyl-6- (2-methylbutyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0021" num="0021"><img file="EP1534713B1_D0021.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.01 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide and 450 mg (3.03 mmol) of ethyl 3-methylvalerate. Yield: 88 mg (32% of theory) MS (DCI): m / z = 275 (M + H)<sup>+</sup>M.p .: 86 ° C<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 5.1 (m, 1H), 2.65 (dd, 1H), 2.45 (dd, 1H), 2.15-1.8 (m, 7H), 1.7 ( m, 2H), 1.45-1.15 (m, 2H), 0.9 (m, 6H) ppm.
<u style="single">Example 5</u>
1-Cyclopentyl-6- (3-methylbutyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0022" num="0022"><img file="EP1534713B1_D0022.tif" /></chemistry>
Analogously to Example 1, the product is obtained from 200 mg (1.01 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide and 450 mg (3.03 mmol) of 4-methylvaleric acid ethyl ester. Yield: 165 mg (60% of theory) MS (ESI): m / z = 275 (M + H)<sup>+</sup>M.p .: 133 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 5.1 (m, 1H), 2.6 (m, 2H), 2.2-1.5 (m, 11H), 0.9 (d, 6H, <i>J</i> = 6.5 Hz) ppm.
<u style="single">Example 6</u>
6- (2-Cyclopenten-1-ylmethyl) -1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0023" num="0023"><img file="EP1534713B1_D0023.tif" /></chemistry>
Analogously to Example 1, the product is based on 200 mg (1.01 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide and 446 mg (1.82 mmol, 95% pure) of 2-cyclopenten-1-yl-acetic acid methyl ester (Lit .: Roenn et al., Tetrahedron Lett. 1995, <i>36</i>, 7749). Yield: 86 mg (30% of theory) MS (ESI): m / z = 285 (M + H)<sup>+</sup>M.p .: 166 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 5.75 (m, 2H), 5.1 (m, 1H), 3.15 (m, 1H), 2.8-2.5 (m, 2H), 2.45- 1.45 (m, 12H) ppm.
<u style="single">Example 7</u>
1- (1-Ethylpropyl) -6- (2-methylbutyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0024" num="0024"><img file="EP1534713B1_D0024.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 445 mg (3.0 mmol) of 3-methylvaleric acid ethyl ester. Yield: 99 mg (36% of theory) MS (ESI): m / z = 277 (M + H)<sup>+</sup>M.p .: 121 ° C<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.5 (m, 1H), 2.6 (dd, 1H), 2.45 (dd, 1H), 2.05-1.7 (m, 5H), 1.45- 1.15 (m, 2H), 0.9 (m, 6H), 0.65 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 8</u>
1- (1-ethylpropyl) -6-isopentyl-1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0025" num="0025"><img file="EP1534713B1_D0025.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 445 mg (3.0 mmol) of 4-methylvaleric acid ethyl ester. Yield: 127 mg (46% of theory) MS (ESI): m / z = 277 (M + H)<sup>+</sup>M.p .: 127 ° C<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.45 (m, 1H), 2.65 (m, 2H), 2.0-1.8 (m, 4H), 1.7-1.5 (m, 3H), 0.9 (d, 6H, <i>J</i> = 7 Hz), 0.6 (t, 6H, <i>J</i> = 6 Hz) ppm.
<u style="single">Example 9</u>
1- (1-ethylpropyl) -6-isobutyl-1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0026" num="0026"><img file="EP1534713B1_D0026.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 464 mg (3.5 mmol) of 3-methylbutyric acid ethyl ester. Yield: 127 mg (48% of theory) MS (ESI): m / z = 263 (M + H)<sup>+</sup>M.p .: 161 ° C<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.45 (m, 1H), 2.5 (m, 2H), 2.15 (m, 1H), 1.95-1.75 (m, 4H), 0.9 ( d, 6H, <i>J</i> = 7 Hz), 0.55 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 10</u>
1- (1-ethylpropyl) -6-propyl-1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0027" num="0027"><img file="EP1534713B1_D0027.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 410 mg (3.5 mmol) of ethyl butyrate. Yield: 159 mg (64% of theory) MS (ESI): m / z = 249 (M + H)<sup>+</sup>M.p .: 127 ° C<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 11.95 (s, 1H), 8.0 (s, 1H), 4.5 (m, 1H), 2.6 (t, 2H, <i>J</i> = 7.5 Hz), 2.0-1.65 (m, 6H), 0.9 (t, 3H, <i>J =</i> 7.5 Hz), 0.6 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 11</u>
1- (1-Ethylpropyl) -6- (tetrahydro-2-furanylmethyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0028" num="0028"><img file="EP1534713B1_D0028.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 553 mg (3.5 mmol) of tetrahydrofuran-2-ylacetic acid ethyl ester. Yield: 202 mg (68% of theory) MS (ESI): m / z = 291 (M + H)<sup>+</sup>M.p .: 136 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.45 (m, 1H), 4.25 (m, 1H), 3.75 (m, 1H), 3.6 (m, 1H), 2.8 (m, 2H), 2.1-1.55 (m, 8H), 0.6 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 12</u>
6- (2-Cyclopenten-1-ylmethyl) -1- (1-ethylpropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0029" num="0029"><img file="EP1534713B1_D0029.tif" /></chemistry>
Analogously to Example 1, the product is started from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazol-4-carboxamide and 490 mg (3.5 mmol) of 2-cyclopenten-1-ylacetic acid methyl ester (lit. .: Roenn et al., Tetrahedron Lett. 1995, 36, 7749). Yield: 111 mg (39% of theory) MS (ESI): m / z = 287 (M + H)<sup>+</sup>M.p .: 128 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 5.8-5.65 (m, 2H), 4.5 (m, 1H), 3.2 (m, 1H), 2.8-2.55 (m, 2H), 2.3 (m, 2H), 2.15-1.8 (m, 5H), 1.55 (m, 1H), 0.65 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 13</u>
Ethyl 4- [1- (1-ethylpropyl) -4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d] pyrimidin-6-yl] butyrate
<chemistry id="chem0030" num="0030"><img file="EP1534713B1_D0030.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 1.13 g (6.0 mmol) of diethyl glutarate. Yield: 46 mg (13% of theory) MS (ESI): m / z = 321 (M + H)<sup>+</sup><sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.5 (m, 1H), 4.2 (q, 2H, <i>J =</i> 7 Hz), 2.7 (t, 2H, <i>J =</i> 7.5 Hz), 2.4 (t, 2H, <i>J =</i> 7 Hz), 2.1-1.75 (m, 6H), 1.2 (t, 3H, <i>J =</i> 7 Hz), 0.65 (t, 6H, <i>J =</i> 7.5 Hz) ppm.
<u style="single">Example 14</u>
Ethyl 4- [1- (1-ethylpropyl) -4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d] pyrimidin-6-yl] propionate
<chemistry id="chem0031" num="0031"><img file="EP1534713B1_D0031.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 1.04 g (6 mmol) of diethyl succinate. Yield: 176 mg (56% of theory) MS (ESI): m / z = 307 (M + H)<sup>+</sup>M.p .: 118 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.1 (s, 1H), 8.0 (s, 1H), 4.4 (m, 1H), 4.0 (q, 2H, <i>J =</i> 7 Hz), 2.9 (m, 2H), 2.8 (m, 2H), 2.0-1.7 (m, 4H), 1.2 (t, 3H, <i>J =</i> 7 Hz), 0.6 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 15</u>
1-Cyclopentyl-6 - [(4-methylcyclohexyl) methyl] -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0032" num="0032"><img file="EP1534713B1_D0032.tif" /></chemistry>
Analogously to Example 1, the product is started from 200 mg (1.0 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide and 664 mg (3.5 mmol) of (4-methylcyclohexyl) ethyl acetate (cis / trans mixture) receive. The product is a mixture of the cis and trans isomers. Yield: 131 mg (41% of theory) MS (ESI): m / z = 315 (M + H)<sup>+</sup>M.p .: 126 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 5.1 (m, 1H), 2.6 (d, 2H, <i>J</i> = 7 Hz), 2.2-0.8 (m, 21H) ppm.
<u style="single">Example 16</u>
1- (1-Ethylpropyl) -6 - [(4-methylcyclohexyl) methyl] -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0033" num="0033"><img file="EP1534713B1_D0033.tif" /></chemistry>
Analogously to Example 1, the product is started from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 413 mg (2.2 mmol) of (4-methylcyclohexyl) ethyl acetate (cis / trans mixture) obtained. The product is a mixture of the cis and trans isomers. Yield: 60 mg (19% of theory) MS (ESI): m / z = 317 (M + H)<sup>+</sup><sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.45 (m, 1H), 2.6 (d, 2H, <i>J</i> = 7 Hz), 2.2-0.8 (m, 17H), 0.6 (t, 6H, <i>J =</i> 7.5 Hz) ppm.
<u style="single">Example 17</u>
1-Cyclopentyl-6- (tetrahydro-2-furanylmethyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0034" num="0034"><img file="EP1534713B1_D0034.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazol-4-carboxamide and 559 mg (3.5 mmol) of tetrahydrofuran-2-ylacetic acid ethyl ester. Yield: 175 mg (60% of theory) MS (ESI): m / z = 289 (M + H)<sup>+</sup>M.p .: 179 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 11.95 (s, 1H), 8.0 (s, 1H), 5.1 (m, 1H), 4.3 (m, 1H), 3.8 (m, 1H), 3.6 (m, 1H), 2.8 (m, 2H), 2.15-1.55 (m, 12H) ppm.
<u style="single">Example 18</u>
Ethyl 4- [1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d] pyrimidin-6-yl] propionate
<chemistry id="chem0035" num="0035"><img file="EP1534713B1_D0035.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 200 mg (1.0 mmol) of 5-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide and 1.05 g (6.05 mmol) of diethyl succinate. Yield: 150 mg (49% of theory) MS (DCI): m / z = 305 (M + H)<sup>+</sup>M.p .: 185 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.1 (s, 1H), 8.0 (s, 1H), 5.05 (m, 1H), 4.05 (q, 2H, <i>J =</i> 7 Hz), 2.9 (m, 2H), 2.8 (m, 2H), 2.15-1.6 (m, 8H), 1.2 (t, 3H, <i>J =</i> 7 Hz) ppm.
<u style="single">Example 19</u>
6- (Cyclohexylmethyl) -1- (1-ethylpropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-thione
<chemistry id="chem0036" num="0036"><img file="EP1534713B1_D0036.tif" /></chemistry>
A solution of 50 mg (0.17 mmol) of 6- (cyclohexylmethyl) -1- (1-ethylpropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one (Example 3) in 1 ml of pyridine is mixed with 74 mg (0.33 mmol, 2 equiv.) of diphosphorus pentasulfide at room temperature and then stirred under reflux overnight. After cooling, the reaction solution is mixed with 20 ml of ice-cold 2.5% sodium hydrogen carbonate solution and extracted three times with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The crude product is purified by preparative HPLC. Yield: 42 mg (80% of theory) MS (DCI): m / z = 319 (M + H)<sup>+</sup><sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 13.4 (s, 1H), 8.2 (s, 1H), 4.45 (m, 1H), 2.7 (d, 2H, <i>J =</i> 7 Hz), 2.0-1.5 (m, 10H), 1.4-0.85 (m, 5H), 0.6 (t, 6H, <i>J =</i> 7.5 Hz) ppm.
<u style="single">Example 20</u>
3- (1-Cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d] pyrimidin-6-yl) -N-phenylpropanamide
<chemistry id="chem0037" num="0037"><img file="EP1534713B1_D0037.tif" /></chemistry>
A solution of 100 mg (0.33 mmol) of 4- [1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d] pyrimidin-6-yl] propionic acid ethyl ester (Example 18) in a mixture 1 ml of ethanol and 0.5 ml of 20% sodium hydroxide solution is stirred at 60 ° C. for 1 h. The organic solvent portion is removed on a rotary evaporator and the solution is adjusted to pH 3 with 1 N hydrochloric acid. The solution is then evaporated to dryness, the residue is stirred with 5 ml of methanol and the solution is filtered. After the methanol has been stripped off, the corresponding carboxylic acid is obtained as a crude product (90 mg, quantitative). 87 mg (0.31 mmol) of the carboxylic acid thus obtained are placed in 6 ml of dichloromethane and first with 119 mg (0.31 mmol, 1 equiv.) HATU and then with 29 mg (0.31 mmol, 1 equiv.) Aniline and 81 mg (0.63 mmol , 2 equiv.) N-ethyldiisopropylamine were added and the mixture was stirred overnight. For working up, the reaction solution is washed twice with saturated sodium bicarbonate solution, the organic phase is dried over sodium sulfate and concentrated in vacuo. The crude product is purified using preparative HPLC. Yield: 25 mg (22% of theory) MS (ESI): m / z = 352 (M + H)<sup>+</sup><sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.05 (s, 1H), 10.1 (s, 1H), 8.0 (s, 1H), 7.6 (d, 2H), 7.3 (t, 2H), 7.0 (t, 1H), 5.0 (m, 1H), 3.0 (m, 2H), 2.8 (m, 2H), 2.05-1.4 (m, 8H) ppm.
<u style="single">Example 21</u>
6- (Cyclopentylmethyl) -1- (1-ethylpropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0038" num="0038"><img file="EP1534713B1_D0038.tif" /></chemistry>
Analogously to Example 1, the product is obtained starting from 150 mg (0.75 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 351 mg (2.25 mmol) of ethyl 2-cyclopentylacetate. Yield: 91 mg (42% of theory) MS (ESI): m / z = 289 (M + H)<sup>+</sup>M.p .: 156 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.0 (s, 1H), 8.0 (s, 1H), 4.45 (m, 1H), 2.7 (d, 2H, <i>J</i> = 7.5 Hz), 2.3 (m, 1H), 2.0-1.45 (m, 10H), 1.35-1.1 (m, 2H), 0.6 (t, 6H, <i>J</i> = 7.5 Hz) ppm.
<u style="single">Example 22</u>
1- (1-Ethylpropyl) -6- (3,3,3-trifluoro-2-methylpropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0039" num="0039"><img file="EP1534713B1_D0039.tif" /></chemistry>
Analogously to Example 1, the product is based on 100 mg (0.51 mmol) of 5-amino-1- (1-ethylpropyl) -1H-pyrazole-4-carboxamide and 469 mg (2.55 mmol) of 3-methyl-4,4,4 -trifluorobutyric acid ethyl ester obtained. Yield: 98 mg (61% of theory) MS (ESI): m / z = 317 (M + H)<sup>+</sup>M.p .: 156 ° C<sup>1</sup>H-NMR (200 MHz, DMSO-d<sub>6</sub>): δ = 12.2 (s, 1H), 8.05 (s, 1H), 4.45 (m, 1H), 3.2-2.9 (m, 2H), 2.7 (m, 1H), 2.0-1.7 (m, 4H), 1.1 (d, 3H), 0.6 (t, 6H) ppm.
<u style="single">Example 23</u>
1- (1-Cyclopentyl) -6- (3,3,3-trifluoro-2-methylpropyl) -1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one
<chemistry id="chem0040" num="0040"><img file="EP1534713B1_D0040.tif" /></chemistry>
Analogously to Example 1, the product is based on 100 mg (0.51 mmol) of 5-amino-1- (1-cyclopentyl) -1H-pyrazole-4-carboxamide and 474 mg (2.57 mmol) of 3-methyl-4,4,4 -trifluorobutyric acid ethyl ester obtained. Yield: 119 mg (73% of theory) MS (ESI): m / z = 315 (M + H)<sup>+</sup>M.p .: 166 ° C<sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>): δ = 12.1 (s, 1H), 8.0 (s, 1H), 5.1 (m, 1H), 3.2-2.95 (m, 2H), 2.7 (m, 1H), 2.2-1.6 (m, 8H) ), 1.1 (d, 3H) ppm.
67 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67
Every citation, both ways
| Document | Relation | Office |
|---|---|---|
| EP0995751A | Cites | European Patent Office (EPO) |
| WO02055082A | Cites | World Intellectual Property Organization (WIPO) |
| WO03037899A | Cites | World Intellectual Property Organization (WIPO) |
| CH396925A | Cites | Switzerland |
| DE1156415B | Cites | Germany |
| US5977118A | Cites | United States of America |
15 members in 8 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 10238724 | Germany | A | |
| 10238724 | Germany | – | |
| 0308979 | European Patent Office (EPO) | W | |
| 10238724 | – | – | – |
| DE2002138724 | – | – | – |
| EP2003008979 | – | – | – |
| WO2003EP08979 | – | – | – |
Members15
| Document | Office | Kind | |
|---|---|---|---|
| DE10238724A1 | Germany | A1 | |
| CA2496308A1 | Canada | A1 | |
| WO2004026876A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2003251706A1 | Australia | A1 | |
| EP1534713A1 | European Patent Office (EPO) | A1 | |
| EP1534713B1This record | European Patent Office (EPO) | B1 | |
| JP2006503051A | Japan | A | |
| DE50302207D1 | Germany | D1 | |
| US2006111372A1 | United States of America | A1 | |
| ES2256797T3 | Spain | T3 | |
| JP4603885B2 | Japan | B2 | |
| CA2496308C | Canada | C | |
| US8039477B2 | United States of America | B2 | |
| US2011294834A1 | United States of America | A1 | |
| US8741907B2 | United States of America | B2 |
33 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Expiry of rightR071 | R071 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Transfer of patentPC2A | PC2A | ES | |
| Transmission of propertyTP | TP | FR | |
| Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)732E | 732E | GB | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Fr: translation filedET | ET | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| Designated contracting states (corrected)RBV | RBV | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1534713
- Publication, DOCDB
- 1534713
- Publication, EPODOC
- EP1534713
- Application
- 3797239
- Application, DOCDB
- 03797239
- Application, EPODOC
- EP20030797239
Titles3
- German
- ALKYL-SUBSTITUIERTE PYRAZOLOPYRIMIDINE
- English
- ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES
- French
- PYRAZOLOPYRIMIDINES SUBSTITUEES PAR ALKYLE
Classification
- CPC, 11
- C07D487/04
- A61P9/10
- A61P21/02
- A61P25/00
- A61P25/14
- A61P25/16
- A61P25/18
- A61P25/28
- A61P27/02
- A61P31/18
- A61P43/00
- IPC, 3
- C07D487 04
- A61K31 519
- A61P25 28
Designated states5
- Contracting states, 5
- Germany
- Spain
- France
- United Kingdom
- Italy
